Multiple Myeloma Clinical Trial
Official title:
A Phase I/II Study Evaluating the Safety and Efficacy of AMD3100 for the Mobilization and Transplantation of HLA-Matched Sibling Donor Hematopoietic Stem Cells in Patients With Advanced Hematological Malignancies
Verified date | June 2017 |
Source | Washington University School of Medicine |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of this study is to determine if peripheral blood cells collected following AMD3100 mobilization can be used safely for hematopoietic cell transplantation into HLA-matched recipients.
Status | Completed |
Enrollment | 92 |
Est. completion date | February 2010 |
Est. primary completion date | December 2009 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 65 Years |
Eligibility |
Inclusion Criteria: Donor criteria: - Donor is 18 to 70 years of age inclusive - If female and of child-bearing age, must be: - non-pregnant, - not breast feeding and - using adequate contraception - Donor is a 6/6 HLA-matched sibling willing to donate peripheral blood stem cell for transplant - Donor must be willing to provide written informed consent. - Adequate cardiac function with no history of congestive heart failure and no history of atrial fibrillation or ventricular tachyarrhythmia. - Adequate renal function as defined by a serum creatinine clearance of =75% of normal (Cockcroft-Gault equation) - Adequate hepatic function as defined by a total bilirubin <2x normal or absence of hepatic fibrosis/cirrhosis - Adequate neurologic function as defined by: - No evidence of a severe central or peripheral neurologic abnormality. - No history of cerebrovascular accident or seizure disorder requiring anticonvulsant medication - Must be HIV-1 & 2 antibody, HIV-1 antigen, and HTLV-I & II antibody sero-negative, by FDA licensed test. - Must have an ECOG performance status of 0 or 1 - Must demonstrate ability to be compliant with study regimen. - Must not have an active infection at the time of study entry - Not have active alcohol or substance abuse within 6 months of study entry - Not currently enrolled in another investigational agent study - Not have any medical condition, which, in the opinion of the clinical investigator, would interfere with his/her evaluation Recipient criteria: - 18 to 65 years of age inclusive - Willing and has a 6/6 HLA-matched sibling willing to donate PBSC for transplant - Provide signed informed consent - If female and of child-bearing age, must be: - non-pregnant, - not breast feeding, and - using adequate contraception Patient must have one of the following diagnoses: - AML in 1st or subsequent remission or in relapse - ALL in 1st or subsequent remission or in relapse - MDS and intermediate 1 or 2, or high risk by the International Prognostic Scoring System - CML in accelerated or second chronic phase - NHL or HD in 2nd or greater complete remission, partial remission,or refractory relapse - CLL Rai Stage 2-4, failing at least 2 prior regimens - MM Stage 2-3 - Adequate cardiac function with a left ventricular ejection fraction = 40% - Adequate pulmonary function defined as: - No severe or symptomatic restrictive or obstructive lung disease, and - formal pulmonary function testing showing an forced expiratory volume at 1 second (FEV1) =50% of predicted and a diffusion capacity of the lung for carbon monoxide (DLCO) =40% of predicted, corrected for hemoglobin - Adequate renal function as defined by a serum creatinine clearance of =75% of normal (Cockcroft-Gault equation) - Adequate hepatic function as defined by a total bilirubin <2x normal or absence of hepatic fibrosis/cirrhosis - Adequate neurologic function as defined by no evidence of a severe central or peripheral neurologic abnormality. Patients with a history of previous central nervous system tumor involvement are eligible provided they are without symptoms or signs and the CNS is now free of disease on lumbar puncture and CT scan of the brain - No evidence of active infection at the time of the transplant preparative regimen or at the time of transplantation - Patient must be HIV-1 & 2 antibody, HIV-1 antigen, and HTLV-I & II antibody sero-negative, by FDA licensed test - ECOG performance status of 0 or 1 - Must demonstrate ability to be compliant with medical regimen - Not have active alcohol or substance abuse within 6 months of study entry - Not be concurrently enrolled on another study involving an investigational agent - Not have any medical condition, which, in the opinion of the clinical investigator, would interfere with the evaluation of the patient |
Country | Name | City | State |
---|---|---|---|
United States | Washington University School of Medicine | Saint Louis | Missouri |
Lead Sponsor | Collaborator |
---|---|
Washington University School of Medicine |
United States,
Devine SM, Flomenberg N, Vesole DH, Liesveld J, Weisdorf D, Badel K, Calandra G, DiPersio JF. Rapid mobilization of CD34+ cells following administration of the CXCR4 antagonist AMD3100 to patients with multiple myeloma and non-Hodgkin's lymphoma. J Clin Oncol. 2004 Mar 15;22(6):1095-102. — View Citation
Devine SM, Vij R, Rettig M, Todt L, McGlauchlen K, Fisher N, Devine H, Link DC, Calandra G, Bridger G, Westervelt P, Dipersio JF. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood. 2008 Aug 15;112(4):990-8. doi: 10.1182/blood-2007-12-130179. Epub 2008 Apr 21. — View Citation
Flomenberg N, Devine SM, Dipersio JF, Liesveld JL, McCarty JM, Rowley SD, Vesole DH, Badel K, Calandra G. The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone. Blood. 2005 Sep 1;106(5):1867-74. Epub 2005 May 12. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Proportion of Donors From Whom a Sufficient Number of Cells for Transplantation Are Collected in no More Than 2 LP Procedures Following Mobilization With AMD3100 (Donor Only) | -Defined as the proportion of donors collecting >2.0x106 CD34+ cells/kg [recipient weight] | Day 1-3 | |
Primary | Proportion of Recipients Who Experience Grade 2-4 Acute GVHD (Recipient Only) | -Incidence and severity of acute GVHD (aGVHD) will be assessed based on the Seattle criteria | By Day 100 after transplant | |
Primary | Proportion of Recipients Who Successfully Engraft by Day +21 After Transplant (Recipient Only) | -Defined as neutrophil count = 500/ul following conditioning regimen induced nadir | Day +21 | |
Secondary | Proportion of Recipients Who Experience Chronic GVHD (Recipient Only) | -Incidence and severity of chronic GVHD will be assessed based on the Seattle criteria | Between Day +100 and +365 post-transplant | |
Secondary | Proportion of Recipients Who Experience Mortality Before Day 100 After Transplant (Recipient Only) | -Death that results from a transplant procedure related complication (e.g. infection, organ failure, hemorrhage, GVHD) rather than from relapse of the underlying disease or an unrelated cause | 100 days after transplant | |
Secondary | Quality of Life During Stem Cell Mobilization (Recipients Only) | 48-72 hours after last dose of AMD3100 | ||
Secondary | Proportion of Donors Who Experience Infusional Toxicity (Donor Only) | -Defined as hypersensitivity reactions. Evaluated by physical exam, blood pressure, heart rate, respirations and temperature one hour prior to the infusion and then 15 minutes, 30 minutes, one hour, 2 hours, and 4 hours post-infusion | Day +1 to +3 (SC donor arm) and Day -3 to +3 (IV donor arm) | |
Secondary | To Determine the Pharmacokinetics of IV AMD3100 (IV Donor Arm Only) as Measured by Cmax | -Blood for pharmacokinetics were drawn prior to infusion, 15 minutes after infusion, 30 minutes after infusion, 45 minutes after infusion, 1 hour after infusion, 2 hours after infusion, 4 hours after infusion, 6 hours after infusions, and 24 hours after infusion | 0 to 24 hours after dose of IV AMD3100 | |
Secondary | To Determine the Pharmacokinetics of IV AMD3100 (IV Donor Arm Only) as Measured by Mean AUC From Time 0 to Infinity | -Blood for pharmacokinetics were drawn prior to infusion, 15 minutes after infusion, 30 minutes after infusion, 45 minutes after infusion, 1 hour after infusion, 2 hours after infusion, 4 hours after infusion, 6 hours after infusions, and 24 hours after infusion | 0 to 24 hours after dose of IV AMD3100 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05027594 -
Ph I Study in Adult Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02412878 -
Once-weekly Versus Twice-weekly Carfilzomib in Combination With Dexamethasone in Adults With Relapsed and Refractory Multiple Myeloma
|
Phase 3 | |
Completed |
NCT01947140 -
Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT05971056 -
Providing Cancer Care Closer to Home for Patients With Multiple Myeloma
|
N/A | |
Recruiting |
NCT05243797 -
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
|
Phase 3 | |
Active, not recruiting |
NCT04555551 -
MCARH109 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of Multiple Myeloma
|
Phase 1 | |
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Completed |
NCT02916979 -
Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG
|
Phase 1 | |
Recruiting |
NCT03570983 -
A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion
|
Phase 2 | |
Terminated |
NCT03399448 -
NY-ESO-1-redirected CRISPR (TCRendo and PD1) Edited T Cells (NYCE T Cells)
|
Phase 1 | |
Completed |
NCT03665155 -
First-in- Human Imaging of Multiple Myeloma Using 89Zr-DFO-daratumumab, a CD38-targeting Monoclonal Antibody
|
Phase 1/Phase 2 | |
Completed |
NCT02812706 -
Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05024045 -
Study of Oral LOXO-338 in Patients With Advanced Blood Cancers
|
Phase 1 | |
Active, not recruiting |
NCT03989414 -
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03792763 -
Denosumab for High Risk SMM and SLiM CRAB Positive, Early Myeloma Patients
|
Phase 2 | |
Withdrawn |
NCT03608501 -
A Study of Ixazomib, Thalidomide and Dexamethasone in Newly Diagnosed and Treatment-naive Multiple Myeloma (MM) Participants Non-eligible for Autologous Stem-cell Transplantation
|
Phase 2 | |
Recruiting |
NCT04537442 -
Clinical Study to Evaluate the Safety and Efficacy of IM21 CAR-T Cells in the Treatment of Elderly Patients With Relapsed or Refractory Multiple Myeloma
|
Phase 1 | |
Completed |
NCT02546167 -
CART-BCMA Cells for Multiple Myeloma
|
Phase 1 |